A Phase 2 interventional study of 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine and 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine in End Stage Renal Disease, sponsored by Iperboreal Pharma Srl. Terminated at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-03.
Sponsored by Iperboreal Pharma Srl · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Kidney Failure, Chronic with a site in Italy — 14 open to participants now, 19 under way, 4 of them phase 3. Kidney Failure, Chronic · Italy.
Among the 75 studies in Kidney Failure, Chronic with a site in Italy, this one is the 53rd largest by enrollment of the 59 interventional ones that give a count, is the only one that started in 2019, is one of 11 in phase 2, and was the 49th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →14 of the 75 studies in Kidney Failure, Chronic with a site in Italy are open now. Recruiting first, the newest first:
Mario Negri Institute for Pharmacological Research · Sites in Italy
Ages 18–90
CSL Behring · Sites in Italy, United States, Argentina and 32 more countries
Ages 18+
UMC Utrecht · Sites in Italy, Netherlands, Spain
Ages 18+
W.L.Gore & Associates · Sites in Italy, Germany, United Kingdom
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–70
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 18 · Phase 4 10
First in 1994; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 59 interventional studies, 164 across the 16 observational. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 75 have an industry lead sponsor. The 10 most frequent:
Iperboreal Pharma Srl is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Iperboreal Pharma Srl has 8 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Failure, Chronic with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03994471Phase 3Iperboreal Pharma SrlEfficacy and Safety of XyloCore Peritoneal Dialysis Solution. | 2026-12-31 |
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT05612022Mario Negri Institute for Pharmacological ResearchAcoustic Analysis of VA Sounds | 2026-12 |
| NCT04360694Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariRandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE) | 2026-12-31 |
| NCT05753930Hansa Biopharma ABImlifidase Prior to Kidney Transplant in Highly Sensitised Children | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 75 studies in Kidney Failure, Chronic with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, randomized, controlled clinical trial. The aim is to compare the effects of the peritoneal dialysis solution IPX15, containing glucose (0.5%), xylitol (1.5%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 2.5% glucose PD solution), for the nocturnal exchange with the PD solution IPX07, containing glucose (0.5%), xylitol (0.7%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 1.5% glucose PD solution), for the diurnal (short dwell) exchanges. Planned total recruitment is 40 patients with stable end-stage renal disease (ESRD) treated by continuous ambulatory peritoneal dialysis (CAPD). Treatment duration will be 4 weeks plus a 4 weeks safety follow up with no treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive treatment with the experimental solution for nocturnal (long-dwell) exchange. For daily (short-dwell) exchanges, all patients will continue the 1 to 3 bags of glucose peritoneal dialysis solution as for their pre-randomization prescription.
Drug: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
Patients will receive 1 to 3 daily (short-dwell) exchanges with the experimental solution (the number of exchanges will be based on their pre-randomization prescription). All patients will receive icodextrin for nocturnal (long-dwell) exchange.
Drug: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
Drug page: XylitolStudies of XylitolXylitol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
One bag for nocturnal (long-dwell) exchange.
Also known as: IPX15
Drug page: XylitolStudies of XylitolXylitol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
One to three, daily (short-dwell) exchanges
Also known as: IPX07
Daily ultrafiltration volume
Change from baseline
Time frame: 28 days
Peritoneal equilibration test
Change from baseline
Time frame: 28 days
Weekly total urea Kt/V
Change from baseline
Time frame: 28 days
Weekly total creatinine clearance
Change from baseline
Time frame: 28 days
Adverse Events
Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected, recorded and followed as appropriate.
Time frame: 2 months
Ran from Sep 2019 to primary completion in Aug 2022, 35 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xylitol
Iperboreal Pharma Srl